



Elenco Poster

ID	N. pgm	Title	Author
Antiretroviral therapy			
1	P 1	HIV-1 RNA levels in semen of people on "short-cycle" antiretroviral therapy	Massimiliano Lanzafame, Trento
12	P 2	Efficacy and safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in people living with HIV-1 aged over 65 years	Leonardo Calza, Bologna
35	P 3	Real-world data on the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): 24-month results of the Italian BICSTaR cohort	Annalisa Saracino, Bari
50	P 4	Probability of starting 2DR vs 3DR regimens in ART-naïve and ART-experienced PLWH before and after the COVID-19 pandemic	Nicola Gianotti, Milano
60	P 5	Physical activity, oxidative stress and antiretroviral therapy in people living with HIV: a multidisciplinary pilot study in people switching to double therapy	Jessica Cusato, Torino
63	P 6	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a pregnant woman with drug resistant HIV-1 infection: A case report	Agnese Giaccone, Napoli
65	P 7	To enDORse Doravirine use in antiretroviral treatment?	Chiara Papalini, Perugia
70	P 8	Effectiveness of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced patients	Sara Tordi, Perugia
71	P 9	Immuno-virological stability in patient with Multi-drug-Resistant HIV and history of poliallergy and intolerance to several antiretroviral drugs	Riccardo Riccardi, Bologna
76	P 10	Long-acting cabotegravir-rilpivirine in highly experienced PLWHIV: the role of Directly Observed Treatment (DOT) in overcoming barriers to adherence	Valentina Iannone, Roma
77	P 11	Satisfaction, clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in a real-life cohort of people living with HIV	Maria Mazzitelli, Padova
82	P 12	Clinical and economic evaluation of dual therapies in cART-experienced HIV positive patients	Sara Palantone, Brindisi
96	P 13	HIV-DNA trend in ART-experienced PLWH switching to injectable long-acting antiretroviral therapies with CAB+RPV: 12-week results in a real-life setting	Francesca Lombardi, Roma
125	P 14	Efficacy and safety of a switch to doravirine and dolutegravir combination in HIV-1-infected patients in a single Italian center: a cohort data analysis	Filippo Lagi, Firenze
185	P 15	Comparing efficacy, safety, and tolerability of 3TC/DTG, TAF/3TC/DOR, and TAF/FTC/BIC in switch strategy of virologically suppressed HIV-infected people	Damiano Farinacci, Viterbo
196	P 16	Risk of failure in dual therapy versus triple therapy in viro-suppressed HIV patients switched to CAB or DTV dual regimens: a systematic review and meta-analysis	Verdiana Zollo, Napoli
201	P 17	Significant CD4+ T-cell increase in Women Living With HIV (WLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): multi-center real-world retrospective longitudinal study	Manuela Ceccarelli, Catania
218	P 18	Virological rebound and the use of dietary supplements in people living with HIV: results of a survey	Sara Esperti, Modena
221	P 19	INSTI resistance mutations emerging while on DTG/3TC dual therapy	Federico Conti, Lecco
241	P 20	Real-life experience of doravirine-based regimens in a cohort living with HIV	Neva Braccialarghe, Roma
268	P 21	Efficacy and safety of dolutegravir/lamivudine in a patient with HIV following sleeve gastrectomy	Giuseppe De Simone, Roma
272	P 22	A retrospective cohort analysis to evaluate the barriers and facilitators encountered by HIV-positive patients undergoing HAART regimen and clinical outcomes	Lucia Appolloni, Bologna



Elenco Poster

ID	N. pgm	Title	Author
285	P 23	Fostemsavir, a new antiretroviral molecule for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: data from clinical practice	Pierluigi Francesco Salvo, Roma
293	P 24	Experience with the use of prolonged-release injectable CAB/RPV in outpatients	Nicoletta Bobbio, Genova
314	P 25	Efficacy, tolerability, safety and adherence to dolutegravir/lamivudine as first-line regimen in the real life setting	Matilde Quaranta, Torino
323	P 26	Acceptability of long-acting injectable antiretroviral therapy (LAI-ART) in people living with HIV	Stefania Arsuffi, Brescia
329	P 27	Will Lenacapavir save us? Compassionate use in heavily treatment-experienced patients with multi-drug resistant HIV infection: a narrative description of the Italian experience	Maria Chiara Ottino, Torino
359	P 28	Real Life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine: new era of ART	Serena Spampinato, Messina
376	P 29	Bictegravir versus Dolutegravir-based regimen in the setting of Rapid ART Initiation: 48-week analysis in a one clinical center	Adriana Cervo, Modena
377	P 30	Outcome of DRV/cobicistat-based regimens in HIV-infected people who experienced virological failure	Nicola Gianotti, Milano
404	P 31	The impact of Doravirine on lipid metabolism: a real-life study	Giacomo Valenti, Palermo
431	P 32	Cardiovascular risk and ARV: an observational study of PLWH with PI based regimen versus INSTI and NNRTI based regimens	Nicola Leoni, Cagliari
447	P 33	Long-acting injectable CAB/RPV vs DTG/RPV: two sides of similar two-drugs regimens	Claudia Bartalucci, Genova
454	P 34	Dual therapy vs triple therapy in experienced PLWH: a multicentre one-year long observational study	Ylenia Russotto, Messina
459	P 35	Safe switch to dual therapy in HIV vertically transmitted young patients	Giulia Meraviglia, Milano
464	P 36	PWH pioneers of cabotegravir and rilpivirine long-acting therapy in SCOLTA: who are they?	Claudia Bartalucci, Genova
468	P 37	CD4 and CD4/CD8 ratio gain in PLWH treated with fostemsavir: results from the PRESTIGIO Registry	Rebecka Papaioannu Borjesson, Milano
494	P 38	Clinical Trials versus Real-Life: Similarities and Differences of patients receiving LA CAB/RPV in a large clinical centre	Maria Vittoria Cossu, Milano
499	P 39	"Test and treat strategy": evaluation data from a multicenter Italian cohort	Andrea Carbone, Roma
507	P 40	Antiretroviral therapy is associated with Sexual Dysfunction and paresthesias	Valentina Vola, Roma
516	P 41	Rescue therapy with Ibalizumab in HIV MDR patient	Salvatore Martini, Napoli
528	P 42	Analysis of determinants of c-ART switch strategies in PLWH in post-COVID-19 era: results from a real-life retrospective study from a tertiary University center in Italy	Emanuela Zappulo, Napoli
530	P 43	Immune reconstitution and safe metabolic profile after the switch to bictegravir/emtricitabine/tenofovir alafenamide fumarate among virologically controlled PLWH: a 96 week update from BICTEL cohort	Julieta Morcos, Roma
537	P 44	CMV re-activation in patients on triple ART switching to B/F/TAF or DTG/3TC: a substudy of the DEBATE Trial	Andrea Cossarizza, Modena



Elenco Poster

ID	N. pgm	Title	Author
Clinical HIV			
16	P 45	Clinical/therapeutic correlates of anxiety and depression in people living with HIV	Francesca Portesani, Torino
53	P 46	HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG	Vincenzo Malagnino, Roma
73	P 47	Prevalence and risk factors for sleep disturbances in PLWH: preliminary results from an observational study	Giuseppe Bruno, Taranto
86	P 48	Impact of SARS-CoV2 pandemic on immune, viral and metabolic status in an Umbrian PLWH cohort	Debora Altobelli, Perugia
109	P 49	Cerebrospinal fluid drain infection caused by pandrug-resistant Staphylococcus epidermidis treated with ceftaroline in combination with fosfomycin and vancomycin in a PLWHIV with AIDS-defining illness	Eugenia Magrini, Roma
112	P 50	A Case of Central Nervous System Infection Diagnosed as Frontotemporal Dementia	Elena Staffilano, Torino
126	P 51	Cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of virologically suppressed PLWHIV	Arturo Ciccullo, L'Aquila
139	P 52	Aging and HIV: between gaps and perspectives	Giovanni Guaraldi, Milano
167	P 53	Study of a novel combination of immunovirologic and genetic parameters in early--treated HIV--1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predictive of post--treatment control (PCT)	Francesca Sironi, Milano
202	P 54	Viro-immunologic pre-treatment predictors of suboptimal viral suppression at 48 weeks of antiretroviral therapy	Paola Saltini, Milano
203	P 55	Cryptococcal meningitis as the first clinical presentation of HIV infection	Carla Frisenda, Chieti
205	P 56	Prognostic factors of CD4 recovery after 12 months of treatment in a cohort of HIV -1 positive patients	Maria Aurora Carleo, Napoli
206	P 57	Survival of HIV/HCV co-infected individuals received liver transplantation in the post-DAA era in Modena	Adriana Cervo, Modena
211	P 58	Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort	Paolo Fusco, Catanzaro
259	P 59	Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report	Francesco Lamanna, Roma
260	P 60	Tubercular rhombencephalitis and ocular syphilis, with possible central nervous system compartmentalization, in a newly diagnosed AIDS patient	Martina Moccione, Roma
276	P 61	Identikit of the HIV patient with acute pathology: epidemiology and clinical characteristics of HIV patients hospitalized in the last year in an Italian University Hospital	Paolo Mantini, Ancona
300	P 62	A case of PCP in a patient with undiagnosed HIV infection	Andrea Zarroli, Chieti
335	P 63	An unusual increase in Kaposi Sarcoma diagnosis in naïve PLWH in the last year in our area. Did the doctors forget this cancer or is it just another late gift of the pandemic?	Barbara Bellocchi, Catania
357	P 64	Reasons for long-acting treatment refusal despite eligibility in a cohort of people living with HIV	Samuele Gardin, Padova
358	P 65	Progressive disseminated histoplasmosis in patients living with HIV: case series and review of literature in non-endemic areas	Dimitra Kontogiannis, Roma
364	P 66	A case of HIV-2 infection in an African man resident in Italy for a long time	Domenico Benvenuto, Roma



Elenco Poster

ID	N. pgm	Title	Author
406	P 67	EBV-related smooth muscle leiomyosarcoma, disseminated non tuberculous mycobacterial infection and Kaposi's sarcoma in AIDS: a case report	Maria Clara Chionsini, Bologna
430	P 68	The two sides of doravirine-based regimens: a descriptive study focusing on kidney function and lipidic profile	Marianna Menozzi, Modena
448	P 69	Serodiscordant twins: a case report of vertical HIV transmission and a minireview of the literature	Monia Alfonzo, Palermo
456	P 70	Extracerebral toxoplasmosis in AIDS: a rare case of T. gondii myositis	Giulia Lingua, Torino
471	P 71	Varicella-zoster virus is an important but often forgotten pathogen in people living with HIV	R. Alessandro Cavasio, Roma
472	P 72	Should echo-doppler of the supra aortic vessels be considered as a screening test in all patients or only in those with a significant cardiovascular risk prediction by Framingham score?	Gabriele Bruno, Catania
478	P 73	Next generation sequencing in the HIV-infected naive patient: a single centre performance evaluation	Matteo Cerchiaro, Genova
493	P 74	Demographical, clinical, and immunological characteristics of c-ART naive patients and risk factors of advanced disease across the years: preliminary results from a tertiary University hospital in Italy	Emanuela Zappulo, Napoli
500	P 75	Characterization and role of HIV-DNA minority mutations in a long-term treated paediatric patients cohort	Luna Colagrossi, Roma
512	P 76	Evaluation of the clinical presentation of naive HIV patients in the pre-Covid era vs those enrolled in the Covid era: data from a Neapolitan multicenter cohort	Salvatore Martini, Napoli
521	P 77	Management and outcome of pregnancy in HIV-infected women in a northern Italian hospital	Chiara Russo, Genova



Elenco Poster

ID	N. pgm	Title	Author
Comorbidities			
5	P 78	Incidence and outcome of TB/HIV co-infection in a rural area of Senegal: a 13-year retrospective study	Maddalena Giglia, Bologna
6	P 79	Prevalence and type of sleep disturbances in a modern cohort of people living with HIV	Maria Mazzitelli, Padova
13	P 80	Improvement in insulin sensitivity after the switch from dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide to doravirine/tenofovir disoproxil fumarate/lamivudine in HIV-infected patients with weight gain	Leonardo Calza, Bologna
34	P 81	Complete remission of polyarteritis nodosa using etanercept in a HIV positive patient: a case report	Michele Gilio, Potenza
36	P 82	Liver fibrosis assesment by fibrosis4 index and correlation with cardiovascular risk in people living with HIV	Costanza Bertoni, Milano
58	P 83	Metabolic, hormonal, vascular and psychological characterization of Erectile Dysfunction in young man living with HIV: preliminary results of a cross-sectional ongoing study	Giorgio Tiecco, Brescia
64	P 84	Sleep disorders and antiretroviral therapy: a real-life study	Luca Pipitò, Palermo
68	P 85	Erectile Dysfunction in young men with vertically acquired HIV infection: a retrospective study	Cosimo Colangelo, Brescia
69	P 86	Polypharmacy and aging in people living with HIV: 6 years of experience in a multidisciplinary outpatient clinic	Cristina Gervasoni, Milano
101	P 87	Evaluation of lipid profile and intima media thickness in HIV experienced patients treated with PI-based regimens vs PI-sparing regimens	Maria Grazia Palamone, Napoli
107	P 88	Vertebral osteomyelitis from Mycobacterium avium complex in ID acquired, six years after immunological recovery	Viola Gennaro, Torino
146	P 89	Liver enzyme variation after switching to Emtricitabine/Tenofovir Alafenamide/Bictegravir is associated with Glucose increase in a real-life cohort	Nicola Squillace, Monza
166	P 90	Weight gain in PLWH: role of multidisciplinary approach	Maria Aurora Carleo, Napoli
207	P 91	Correlating Qualitative/Quantitative Quantiferon- Tb Gold Plus Results And Cd4 +/Cd8+ Count: A Retrospective Study In A Hiv Cohort	Angelo Tavano, Pavia
214	P 92	Is CAP (Controlled Attenuation Parameter) a useful test in the management of older HIV positive patients?	Edoardo Paolo Drago, Foggia
225	P 93	Psychological well-being in a cohort of people living with HIV: a single center study	Denise D'Elia, Udine
240	P 94	NAFLD In People Living With HIV (PLHIV): risk factors associated with steatosis confirmed by fibroscan	Nicholas Brian Bana, Monza
246	P 95	Correlation between bone and miointimal damage in patients with HIV	Addolorata Masiello, Caserta
275	P 96	A Nocardia From Nowhere	Alessandro Luciano Croci, Bologna
352	P 97	Salmonella enteriditis spondylodiscitis in a liver transplanted HIV-HBV-HCV-HDV patient: a case report	Andrea Iannacone, Ancona
361	P 98	Not all that's indolent can't hurt: an aggressive case of EBV-positive mucocutaneous ulcer (EBVMCU) in an HIV naive patient	Pietro Valsecchi, Pavia
400	P 99	A multidisciplinary approach for an uncommon case of infective endocarditis	Alessandro Cornelli, Napoli
405	P 100	The impact on body weight and body mass index of glucagon-like peptide 1 receptor agonists in diabetic people living with HIV	Martina Bottanelli, Milano



Elenco Poster

ID	N. pgm	Title	Author
433	P 101	Cancer in People Living With HIV: study of the outpatient population at Tor Vergata Hospital	Veronica D'Aquila , Roma
438	P 102	Cancers of the skin and mucous membranes in HIV-infected patients compared to the general population	Giulia Ciccarese, Foggia
443	P 103	Prevalence of metabolic syndrome in a cohort of people living with HIV: lifestyle and risk factors analysis	Arianna Narducci, Foggia
485	P 104	Efficacy and safety of dolutegravir + lamivudine in patients in onco-haematological treatment	Layla Pagnucco, Pavia
491	P 105	Statins and Aspirin use in people living with HIV (PLWH): gap between European AIDS Clinical Society guidelines and clinical practice	Carmen Giarratana, Catania
518	P 106	Evaluation of intimal media thickness in HIV-experienced patients treated with triple therapy vs patients treated with dual therapy: multicenter cohort data	Salvatore Martini, Napoli
520	P 107	Peritoneal-pleural tuberculosis in a HIV positive and cirrhotic patient	Federica Malerba, Bologna
524	P 108	Depressive disorder and vitamin D in a group of HIV patients in cART: dual therapy versus triple therapy	Livia Moffa, Chieti
527	P 109	Male breast cancer in a patient with HIV-HCV coinfection: a case report	Nicolò Amarasinghe, Pavia



Elenco Poster

ID	N. pgm	Title	Author
COVID-19			
4	P 110	Scaling up COVID 19 response among adolescents and young people in Limbe health district of Cameroon	Alemju Fontu, Buea
7	P 111	Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study	Maria Mazzitelli, Padova
33	P 112	Prognostic value of creatinine levels at admission on disease progression and mortality in patients with COVID-19. An observational retrospective study	Federica Ciminelli, Napoli
41	P 113	Long-covid characterization in a cohort of patients from Campania: prospective cohort study results	Francesco Caruso, Napoli
43	P 114	Risk factors for acute kidney injury (AKI) in patients hospitalized with COVID-19: results of a retrospective cohort study	Francesca Ambrisi, Napoli
59	P 115	The impact of co-infections and antibiotic use in SARS-CoV-2 hospitalized patients at Policlinico Tor Vergata Hospital, Rome, Italy	Andrea Di Lorenzo, Roma
66	P 116	Predictors of SARS-CoV-2 infection in treatment-experienced PLWHIV: case-control study	Valentina Iannone, Roma
80	P 117	Delta variant as a strong predictor of long COVID incidence and neuropsychiatric symptomatology: data from a large, multicenter, prospective cohort study	Luisa Frallonardo, Bari
81	P 118	Impact of COVID-19 on the long-term outcome among PLWH: a real-life study	Melania Degli Antoni, Brescia
85	P 119	COVID-19 in immunocompromised patients: what is the role of passive and active immunisation?	Luigi Coppola, Roma
102	P 120	Factors associated with anti-spike SARS-CoV2 antibody titer among patients hospitalized with COVID-19-related pneumonia	Giustina Lo Cascio, Milano
115	P 121	Epidemiological and clinical factors related to late negativization of SARS-CoV 2 swab	Pierantonio Grimaldi, Napoli
117	P 122	Early treatment of COVID-19 in out-patient setting: a single-center retrospective study	Erica Binetti, Roma
118	P 123	Glucocorticoids in diabetic COVID-19 patients: efficacy and safety of Deflazacort	Alessandro Di Gasbarro, Chieti
120	P 124	Post-COVID-19 Syndrome: a retrospective study of our center's patients	Giorgia Taraschi, Chieti
134	P 125	Impact of SARS-CoV2 infection in PLWH in the vaccine era	Laura Comi, Bergamo
147	P 126	Incidence and burden of long COVID in Africa: a systematic review and meta-analysis	Roberta Novara, Bari
169	P 127	Vaccination against SARS-CoV2: are antibodies predictive of protection?	Stefania Dispinseri, Milano
172	P 128	Survival stratification according to soluble urokinase plasminogen activator receptor (suPAR) levels of COVID-19 hospitalised patients	Gianluca Gazzaniga, Milano
174	P 129	Does remdesivir affect renal function in SARS-CoV2 infected patients? Real life data in a single center in Perugia	Elisabetta Svizzeretto, Perugia
178	P 130	Which is the efficacy of Sotrovimab in reducing disease progression and death during the Omicron era? Answer from a real-life study	Andrea De Vito, Sassari
186	P 131	Treatment with nirmatrelvir/ritonavir prevented hospitalizations and deaths in patients diagnosed with COVID-19 at a residential care facility in Milan, Italy	Laura Pezzati, Legnano
192	P 132	Oldest old outpatients with mild-moderate SARS-CoV-2 infection treated with monoclonal antibodies: a real life single center study	Nicola Bonadiman, Padova



Elenco Poster

ID	N. pgm	Title	Author
217	P 133	Relationship between ultrasensitive SARS-CoV-2 viraemia, inflammatory parameters and lymphocyte stimulation test	Alessandra Imeneo , Roma
238	P 134	SARS CoV 2 infection in a patient affected by cerebral amyloid angiopathy: case report and literature commentary	Anna Maria Spera, Salerno
257	P 135	Remdesivir-nirmatrelvir combination: in vitro activity and a case report	Anna Gidari, Perugia
261	P 136	Correlation between IgM and IgG anti-Sars-Cov-2 and clinical Covid stadiation	Alessandra Di Fraia, Napoli
264	P 137	Immunogenicity of primary two dose cycle and three dose of mRNA vaccine in treated solid cancer patients	Arianna Gabrieli, Milano
267	P 138	Clinical efficacy of two doses of mRNA-based vaccines COVID-19 for solid cancer patients on treatment	Arianna Gabrieli, Milano
289	P 139	Incidence of Post-COVID conditions in people treated with monlupiravir: a single-center experience	Andrea De Vito, Sassari
298	P 140	SARS-CoV-2 infection and solid organ transplant recipients: a single center experience	Francesco Peracchi, Monza
302	P 141	Keystone bacterial species of altered blood and oral microbiota profile during SARS-CoV-2 infection	Letizia Santinelli, Roma
303	P 142	Latina score for discrimination between progressor and non progressor SARS-CoV-2 infected patients	Paola Zuccala', Latina
307	P 143	A retrospective cohort study to understand the impact of the drugs indicated in the early treatment of Sars-CoV-2 disease and the risk of hospitalization	Giulia Pensalfine, Bologna
308	P 144	Impact of COVID pandemic and COVID disease on aging trajectories in older nursing homes residents in Italy	Federico Romani, Modena
310	P 145	Use of a rapid molecular multiplex real time PCR test for the detection of SARS-CoV-2, influenza A/B and respiratory syncytial virus	Chiara Orlandi, Urbino
312	P 146	Active metabolite of Erdosteine (MET-1) inhibits SARS-CoV-2 infection and modulates inflammatory state in A549 cells	Sergio Strizzi, Milano
315	P 147	SARS-CoV-2 infection in Chimeric Antigen receptor T cell patients	Federico Frondizi, Roma
319	P 148	Alpha-synuclein multimer/monomer ratio is an important determinant of Type-I Interferon response against SARS-CoV-2 infection	Fiona Limanaqi, Milano
321	P 149	Early SARS-CoV-2 Treatment in Solid Organ Transplant recipients: a Single-Centre Retrospective Cohort Study during the Omicron era	Eugenia Milozzi, Roma
332	P 150	Characterization of the second, third and fourth wave of COVID 19 occurring in Campania: results of a cohort study	Roberta Palladino, Napoli
342	P 151	Anti-SARS-CoV-2 humoral and cellular immune responses in health care workers 4 months after a 4th vaccination with the Pfizer-BioNTech bivalent vaccine	Alessandra Ruggiero, Verona
356	P 152	Analysis of T cell receptor repertoire in vaccinated and unvaccinated COVID-19 patients	Salvatore Rotundo, Catanzaro
366	P 153	Risk factors of prolonged SARS-CoV-2 infection in patients with mild symptoms, a retrospective analysis	Filomena Milite, Napoli
370	P 154	Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5 in booster vaccinated immunocompromised patients at the Infectious Diseases Clinic of Perugia	Elisabetta Schiaroli, Perugia
384	P 155	A refine analysis on SARS-CoV-2 omicron variability in infected immunocompromised individuals	Maria Concetta Bellocchi, Roma



Elenco Poster

ID	N. pgm	Title	Author
387	P 156	A data-driven identification of PASC clusters to predict recovery	Federico Motta, Modena
388	P 157	Combination therapy to eradicate sarscov2 infection in a patient treated with CAR-T	Mariantonietta Pisaturo, Napoli
390	P 158	The hypothesis of dysergic diathesis in long-COVID syndrome and in SARS-Cov2 post-vaccination reactions: preliminary data from a prospective cohort study	Davide Recinelli, Pescara
393	P 159	Active role of Telefono Verde AIDS and IST in the communication on COVID-19 pandemic in Italy	Anna Colucci, Roma
394	P 160	SARS-CoV-2 seroprevalence and associated factors in young people living with HIV attending Youth-friendly Health services in the Sofala province, Mozambique	Virginia Casigliani, Pisa
407	P 161	Are there any differences in effectiveness between available antivirals and monoclonal antibodies treatments in paucisymptomatic SARS-CoV-2 infected patients? A real life experience	Lucia Galli, Milano
408	P 162	Monoclonal antibodies (mAbs) and antiviral drugs for SARS-CoV2 treatment in patients with oncohematological disease	Sara Giovanna De Maria, Roma
413	P 163	Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and lung involvement in acute and post-acute SARS-CoV-2 infection	Maria Antonella Zingaropoli, Roma
424	P 164	Risk-factors for mortality of COVID-19 in hematologic patients: a multivariate analysis in Galliera hospital COVID-19 cohort	Silvia Boni, Genova
426	P 165	Remdesivir 3-day course reduces the risk of disease progression in a real-life matched cohort	Alessandra Bitti, Sassari
428	P 166	SARS-CoV2 infection in dialysis patients: early treatment impact on clinical outcome	Sara Corazza, Roma
434	P 167	Sotrovimab vs Tixagevimab/Cilgavimab in outpatients with COVID-19: Clinical practice	Francesco Rosario Paolo Ieva, Foggia
435	P 168	A comparative focus between immunocompromised and immunocompetent patients with COVID19 infection receiving early antiviral therapy in a real-world scenario	Silvia Garattini, Latina
439	P 169	The impact of cognitive reserve on neurocognitive impairment during long-COVID -19	Giulia Del Duca, Roma
451	P 170	Recurrent COVID-19 infection in a patient with post-remission onco-haematological diseases	Alice Fulgione, Napoli
453	P 171	Is it possible to identify predictive factors for COVID-19 severe disease and mortality in the post-vaccine era? A real-life single cohort Italian experience	Chiara Fusetti, Milano
457	P 172	The impact and outcome of early treatment for COVID-19 in transplanted patients: a real life study	Alessandra Grimaldi, Roma
469	P 173	Risk Factors Associated with Long COVID: A Retrospective Study	Patrizia Pasculli, Roma
484	P 174	Real-World Use of Sotrovimab in outpatients and hospitalized COVID-19 during Omicron pandemic wave	Chiara Muscatello, Foggia
487	P 175	Sotrovimab treatment in Severe COVID-19	Chiara Muscatello, Foggia
489	P 176	A SARS-CoV-2 cluster in patients with onco-hematological disease	Andrea Gasperin, Latina
501	P 177	SARS-CoV-2 infection in oncohematological patients: a real-world experience	Francesco Izzo, Roma
502	P 178	Characterization and monitoring of post-acute sequelae of SARS-CoV-2 infection (PASC) through a voice assistant platform: an ecological prospective study	Licia Gozzi, Modena



Elenco Poster

ID	N. pgm	Title	Author
503	P 179	Importance of use of antiviral and monoclonal therapies in patients at risk of developing severe disease and complications from SARS-CoV2 infection: experience of COVID-DH of Pescara Civil Hospital	Dario Antonio Silletta, Pescara
508	P 180	The clinical management of fully vaccinated patients at high risk of disease progression with symptomatic COVID-19 infection at ASST Lecco: Real-life experience	Federico Conti, Lecco
509	P 181	Evaluation of the immune response to SARS-CoV-2 vaccination one year after the booster dose in oncology patients	Roberta Campagna, Roma
526	P 182	SARS-CoV-2 infection in patients with haematological malignancies: in search of lost timing?	Roberta Astorri, Napoli



Elenco Poster

ID	N. pgm	Title	Author
Epidemiology and Prevention			
10	P 183	Convenient&Quick - Let's do it in Pharmacies	Rosario Galipò, Roma
18	P 184	Sexually Transmitted Infections' (STIs) screening offered by not-for-profit sector entities during the COVID-19 pandemic: a descriptive observational study of the population accessing a LGBT+ dedicated service	Nicolò Piazza, Caserta
21	P 185	The future impact of SARS-CoV-2 on sexually transmitted diseases spread	Ilaria Uccella, Frosinone
28	P 186	Human papillomavirus vaccine uptake before and after the implementation of an on-site vaccination service at an HIV clinic in Milan, Italy: a retrospective observational study	Andrea Giacomelli, Milano
31	P 187	Incidence of HCV and HIV in the female prison population: Analysis of two Italian centers	Valentina Manca, Sassari
91	P 188	Detection of asymptomatic Mpox virus infection in high-risk men who have sex with men: a prospective analysis	Roberto Rossotti, Milano
94	P 189	Life expectancy and determinants of increased risk of death in PLWH	Franco Maggiolo, Bergamo
111	P 190	Use of MVA-BN vaccine in the context of the current Mpox outbreak: early experience of an infectious and tropical diseases unit in Florence, Italy	Filippo Lagi, Firenze
130	P 191	Outbreak of HIV among people who inject drugs discovered through phylogenetic analysis: are we seeing just the top of the iceberg?	Alessandro Soria, Monza
215	P 192	Evaluation of the acceptance of salivary rapid HIV tests in the IDU population afferent to the Ser.D. of Treviso	Maria Cristina Rossi, Treviso
224	P 193	Lack of antibody protection for HBV in young people undergoing non-occupational Post-Exposure Prophylaxis (PEP) for HIV in a large tertiary hospital in Milan, Italy	Arianna Liparoti, Milano
239	P 194	High Prevalence of HIV Infection and Late Diagnoses by HIV indicator conditions guided screening in the Emergency Department: Preliminary Results from the INDI Study	Andrea Santoro, Milano
245	P 195	Highlights from an ongoing anal cancer prevention protocol for people living with HIV at the Infectious and Tropical Diseases Unit of Padua University Hospital	Davide Leoni, Padova
249	P 196	Strategies to reduce vaccine hesitancy. First step: know your population. A single center in-depht analysis of PLWHA adherence to vaccination schedule	Gian Carlo Orofino, Torino
330	P 197	Retrospective analysis of accidental and occupational exposures, post-exposure prophylaxis (PEP) prescription and surveillance program in a large Hospital, Northern Italy	Davide Minisci, Brescia
343	P 198	HPV vaccination coverage in MSM living with HIV: a retrospective monocentric study in Northern Italy	Davide Laurenda, Brescia
374	P 199	Do we think enough about strongyloidiasis, schistosomiasis and Chagas disease among HIV-positive migrant patients? Screening ratio and seroprevalence in a tertiary health-care center in Italy	Anna Barbiero, Firenze
375	P 200	Monkeypox vaccination in a cohort of people on pre-exposure prophylaxis (PrEP) or living with HIV infection (PLWH): a retrospective observational study from the Umbria region, Italy	Giulia Quartini, Terni
402	P 201	HIV Testing in the Emergency Department: an effective strategy to increase new diagnoses	Francesco Romano, Roma
483	P 202	HPV vaccination days in HIV and STI outpatient clinic	Anna Carraro, Roma
523	P 203	Missed opportunities in HIV diagnosis: to recognize sentinel conditions for HIV to reduce late presentation in an urban setting in northern Italy	Martina Bavastro, Genova



Elenco Poster

ID	N. pgm	Title	Author
Hepatitis and other viral infections			
9	P 204	An Occult hepatitis B virus Infection Reactivation in an HIV/HCV Coinfected patient during an Immune Reconstitution Inflammatory Syndrome	Marco Di Gregorio, Brescia
14	P 205	Human Orf: an under-recognized and under-reported viral infection	Martina Salvi, Brescia
22	P 206	Evaluation of the effectiveness of a population-based health policy to increase HCV treatment coverage: an interrupted time series analysis	Luca Ceccarelli, Bologna
29	P 207	Evaluation of anti-Mpox IgG development in infected patients	Damiano Farinacci, Viterbo
61	P 208	Performance evaluation of HIV-2 RNA plasma quantification using a commercial RUO RT-PCR assay	Alberto Rizzo, Milano
78	P 209	Inherited chromosomally integrated HHV6: a case report	Gisella D'Aguzzo, Marsala
104	P 210	Early HCV treatment during RCHOP therapy in subjects with non Hodgkin lymphoma	Roberta Palladino, Napoli
121	P 211	Hepatic flare and immune reconstitution in Hepatitis B Virus-Human Immunodeficiency Virus coinfecting patients	Angela Maria Antonia Crea, Roma
168	P 212	Tuscany Region: Epidemiology of Hepatitis C	Maria Paola Tramonti Fantozzi, Pisa
204	P 213	Patient with HCV/HBV-related cirrhosis and colon cancer: a difficult patient to treat	Charikleia Liagkoua, Napoli
242	P 214	Pathways underlying HDV persistence act independently from the extent of HBV reservoir and are sustained by an abundant production of HBsAg derived from integrated HBV-DNA	Romina Salpini, Roma
309	P 215	Kinetics of the three HBsAg isoforms along with HDV-RNA predict virological response in CHD patients treated with bulevirtide up to 96 weeks	Stefano D'Anna, Roma
341	P 216	Identification of novel molecular targets for therapeutic reconstitution of HBV-specific CD8 T cell reactivity in chronic hepatitis B virus infection	Ilaria Montali, Parma
344	P 217	Ecthyma gangrenosum with facial and oral localization in a young neutropenic woman with recent Dengue infection	Francesca Catania, Roma
379	P 218	HCV relapse after sofosbuvir/velpatasvir/voxilaprevir in a patient with chronic lymphocytic leukemia: speculations on a potential cause	Chiara Fusetti, Milano
381	P 219	Preliminary results of a Case Finding and Linkage to Care program for high-risk HCV infected individuals	Francesco Giuseppe Spatola, Napoli
409	P 220	Long-term mortality after HCV eradication among PLWH	Alessia Siribelli, Milano
415	P 221	A pilot intervention for HCV elimination among MSM in Rome: results from a program of micro-elimination of HCV	Pierluca Piselli, Roma
417	P 222	Integration of hepatitis C and addiction treatment in people who injects drugs. The San Patrignano HCV-free and drug-free experience	Pierluca Piselli, Roma
419	P 223	Acute viral hepatitis from HBV due to immune-reconstitution in a patient with pleural tuberculosis receiving treatment	Lorenzo Ansaldo, Roma
475	P 224	A case of congenital CMV infection due to pre-conceptional maternal primary infection: serologic pitfalls in Valacyclovir Era	Alessandra Ricciardi, Pavia
482	P 225	Anti-HBV therapy in hemodialytic patient: a not easy approaches	Rebecca Pesare, Pavia
513	P 226	Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia. Updated data	Lucia Denti, Sassari
515	P 227	Acute HBV hepatitis leading to liver failure: when to treat?	Andrea Gizzi, Palermo



Elenco Poster

ID	N. pgm	Title	Author
Immunopathogenesis and Vaccines			
20	P 228	High frequency of type I Interferon autoantibodies in a cohort of middle-aged people with HIV: a retrospective pilot study	Giorgio Tiecco, Brescia
39	P 229	Viral blips and virologic failures following mpox MVA-BN vaccination among people living with HIV	Angelo Roberto Raccagni, Milano
42	P 230	How COVID-19 asymptomatic infection influence response to BNT162b2 vaccine among Persons Living with HIV (PLWH): data from patients in charge at Cotugno Hospital, Naples, Italy	Francesco Maria Fusco, Napoli
57	P 231	Gut microbiome influences the reservoir in acute, cART-treated HIV	Valeria Bono, Milano
123	P 232	Association between SARS-CoV-2 RNAemia and systemic inflammation in people with HIV hospitalized for acute COVID-19 pneumonia	Matteo Augello, Milano
154	P 233	Heavily Treatment-Experienced (HTE) People Living with HIV (PLWH) with Vertical Transmission and Detectable Viremia do not Display Increased Peripheral Inflammation Markers: Data from the Prestigio Registry	Camilla Tincati, Milano
160	P 234	Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience	Benedetta Trentacapilli, Milano
220	P 235	Determinants of recorded SARS-CoV-2 vaccine uptake among ART-compliant people living with HIV	Grazia Alessio, Roma
222	P 236	Targeting Nef as the Primary Driver of HIV Persistence and Immune Escape	Sateesh Apte, Dover
231	P 237	Tolerability of Shingrix in patients with multiple sclerosis and other neurological diseases on immune modulating treatments	Ilenia Fato, Roma
256	P 238	Antibody response to the third dose of SARS-CoV-2 mRNA vaccine in PLWH on ART at 12 months after its administration	Eeva Tortellini, Roma
286	P 239	Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement	Carmela Pinnetti, Roma
287	P 240	Herpes zoster prevention through administration of recombinant zoster vaccine (RZV) in a cohort of PLWH in Rome	Pierluigi Francesco Salvo, Roma
328	P 241	Serum and Plasma Biomarkers of Central Nervous System Involvement Measured Through Single Molecule Array in PLWH and controls	Jessica Cusato, Torino
421	P 242	Immunization coverage in older people living with HIV in a large Hospital, Northern Italy	Anna Cambianica, Brescia
436	P 243	Immune responses to vaccination in HIV vertically-infected patients: a long term evaluation	Annachiara Zin, Padova
442	P 244	Compliance with immunisation amongst HIV-infected patients and clinicians vaccines offer rates in the HIV Outpatient Clinic of the Valle d'Aosta Region	Manuela Colafigli, Aosta
450	P 245	The impact of HIV-1 infection and sexual orientation on the intestinal microbiota composition in HIV-1 serodiscordant couples	Ginevra Bugani, Roma
534	P 246	Idiopathic CD4 Lymphocytopenia: novel insights into the immunological functions of CD4 T cells	Andrea Lisco, Bethesda



Elenco Poster

ID	N. pgm	Title	Author
PrEP			
11	P 247	Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)	Sandro Mattioli, Bologna
24	P 248	The Anlaids forum may identify new subjects to be addressed for PrEP	Alberto Venturelli, Roma
30	P 249	Pre-Exposure Prophylaxis (PrEP) usage in a MSM adult population: organizational procedures, issues and observations	Alfredo Franco, Napoli
162	P 250	High Propensity to Switch to Long-acting Injectable PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men	Angelo Roberto Raccagni, Milano
187	P 251	Is hypophosphatemia a real contraindication for PrEP? Let's ask the renal tubule	Gabriele Guglielmetti, Novara
198	P 252	Pre-exposure prophylaxis (PrEP): achieved results and what remains to be done	Luigi Coppola, Roma
232	P 253	High interest in long-acting injectable cabotegravir (CAB-LA) among "on demand" PrEP users	Serena Venturelli, Bergamo
295	P 254	PrEP in Eastern Piedmont: STIs and renal safety	Marco Sciarra, Novara
380	P 255	Reasons for leaving a PrEP community-based service: our experience in Bologna, Italy	Carolina Patrucco, Bologna
411	P 256	A descriptive analysis of serum creatinine variation in users assuming TDF-PrEP: a possible role of age and comedication	Maddalena Albertini, Modena
425	P 257	Pre-exposure prophylaxis for HIV and risk of recurrent sexually transmitted infections	Damiano Farinacci, Viterbo



Elenco Poster

ID	N. pgm	Title	Author
Social and behavioural science, marginalized groups, community aspects and community surveys			
3	P 258	Impact of peer education on sexual health knowledge among adolescents and young persons in the Buea subdivision of the South West region of Cameroon: through VCT campaigns	Keteutat Tchato Eric Marot, Buea
8	P 259	Chems & le Holograms	Angela Infante, Roma
15	P 260	THE. M.A.NNA project (Maometto Alla moNtagNa)	Serena Dell'Isola, Viterbo
44	P 261	Young people and HIV - Millennials on HIV/AIDS/STI and emerging needs	Rosario Galipò, Roma
45	P 262	Bringing HIV prevention to schools: data analysis	Federica Rossi, Milano
47	P 263	The non-Italian MSM population within the Rome Checkpoint HIV and STD screening context	Francesco Angeli, Roma
88	P 264	IO C()ENTRO HIV CheckPoint in Genova, Italy: results of first year experience towards future objectives and new operational strategies	Elena Terragna, Genova
89	P 265	Things change. Latest U=U communication campaign of LILA Cagliari	Giacomo Dessì, Cagliari
92	P 266	Supporting Quality of Life: complexities and goals in the experience of a Mindfulness group in a community site	Alessandra Bianchi, Milano
110	P 267	One year experience of the Ancona Checkpoint: first analysis of COBATEST data of population	Sara Caucci, Ancona
119	P 268	Prisoners living with HIV. Retrospective analysis the cascade of care in two penitentiaries in Northern Italy	Anna Cambianica, Brescia
124	P 269	Fifth year of mono symptomatic therapeutical group for chemsex addiction, a roundup	Giorgia Fracca, Milano
133	P 270	Mapping the Status of Services in the Field of Sexual Health and HIV Management in Thirty-One Provincial Capitals of Italy	Carmine Urciuoli, Bologna
137	P 271	Taking it to the Streets: HIV Prevention for Drug Users through Outreach Units in Rome in 2022	Giancarlo Rodoquino, Roma
138	P 272	Breaking barriers to HIV and HCV screening among migrants in Rome	Paola Sammarco, Roma
142	P 273	Transgender and HIV: a case for an inclusive clinical record	Luisa Brogonzoli, Milano
150	P 274	U=U. Cosa sai, cosa non sai	Ada Moznich, Milano
159	P 275	LILA testing services in 2022: observations from experiences of our network	Giacomo Dessì, Cagliari
163	P 276	The Relationship as Outcome Indicator: Person-Based Approach in Rome	Daniela Masci, Roma
173	P 277	"Resilience" – Study on the psychological and practical impact of COVID-19 on the quality of life of people living with HIV	Sabrina Penon, Milano
176	P 278	Conscious sexuality and young people: let's talk about HIV	Alice De Faveri, Torino
181	P 279	How much does stigma weigh in a more informed setting? An online survey	Daniele Calzavara, Milano
182	P 280	Difficult to reach, fragile key populations at high risk: the Bergamo Leaves No One Behind Project	Davide Meli, Bergamo
191	P 281	The two faces/directions of the Bergamo Check Point: young people and key populations	Paolo Meli, Bergamo
209	P 282	Foreigners and their requests to LILA helpline from 2018 to 2022: a comparative analysis	Alice Castellari, Firenze



Elenco Poster

ID	N. pgm	Title	Author
223	P 283	NO ONE LEFT BEHIND - Omphalos LGBTI+ experience, Perugia, Italy. A community-based HIV testing before and after the challenging covid-19 pandemic period (2020). It's time to strengthen the dialogue about sexual health	Anastasia Zoffoli, Perugia
262	P 284	To drink or not to drink. Data from real life and implication for dietitian counselling for PLWHA	Donatella Penoncelli, Torino
270	P 285	Association between Locus of Control, Health Locus of Control, Coping and Resilience in an Italian cohort of people living with HIV	Valentina Massaroni, Roma
274	P 286	The role of emotion dysregulation in patient health engagement and HIV-related symptom distress in an Italian cohort of people living with HIV	Valentina Delle Donne, Roma
291	P 287	Searching for HCV infection: involvement of Therapeutical Communities is mandatory!	Emanuele Pontali, Genova
320	P 288	HIV and HCV awareness and knowledge among the general population in Brescia, Northern Italy	Stefania Arsuffi, Brescia
333	P 289	Late-presenter person living with HIV in detention institute. Case report	Anna D'Angelillo, Viterbo
378	P 290	A friendly, rapid testing and counseling approach to improve linkage to care: a two year experience at Checkpoint and Hospital center	Giulia Mancarella, Latina
397	P 291	Comprehensive Sexuality Education (CSE) in Italian secondary schools: preliminary results of EduForIST2 pilot activity	Alice Chinelli, Pisa
401	P 292	Web Listening to identify the information needs of different targets and detected the barriers to the modification of the HIV behaviors	Anna Colucci, Roma
416	P 293	Impact of COVID-19 on the management of their disease in People living with HIV: preliminary results of semi-structured interviews	Pierluca Piselli, Roma
463	P 294	The role of the psycho-social team of the C.A.M.A. ODV, in 25 years of activity in the "Home treatment of people suffering from AIDS and related pathologies" - Interventions in implementation of the Presidential Decree 09.14.1991 and Ministerial Decree 09.13.1991	Angela Calluso, Bari
466	P 295	The prevention of Sexually transmitted infections (STIs) in new migrant populations. Data from the Perugia Outpatients Clinic	Michele Ramadori, Perugia
481	P 296	Quality of pre- and post-COVID-19 healthcare: the point of view of women living with HIV	Amalia Bove, Roma



Elenco Poster

ID	N. pgm	Title	Author
STIs, Sexually transmitted infections			
51	P 297	Ureaplasma urealyticum: a controversial pathogen to treat. The experience from a difficult-to-reach population	Agnese Colpani, Sassari
90	P 298	Reduction of sexual risky behavior and vaccination do not explain decreased incidence of Mpox among PrEP users attending a community-based facility	Roberto Rossotti, Milano
116	P 299	Monkeypox in a woman with HIV infection: a case report	Stefano Mario Susini, Napoli
129	P 300	Doxycycline oral treatment for latent syphilis: evaluation of outcomes and tolerability	Martina Laura Colombo, Milano
184	P 301	Luetic infection in the present day: characteristics of a cohort of patients diagnosed with syphilis in the Roman suburbs	Marta Zordan, Roma
193	P 302	Prevalence of Human Papillomavirus (HPV) in the Oral swabs of patients at University Hospital of Bari	Daniela Nesta, Bari
194	P 303	Prevalence of seven sexually transmitted pathogens in oral cavity and the impact of a new dedicated ambulatory for STI and Pre-Exposure Prophylaxis (PrEP) in Bari	Mara Lorusso, Bari
216	P 304	Neisseria meningitidis in PrEP users: sexual transmission and isolation of an ESBL positive strain	Giulia Gamboni, Perugia
318	P 305	HIV and Syphilis rapid tests among University students: a prevention and awareness campaign towards sexually transmitted infections	Federica De Gregorio, Foggia
325	P 306	Distinct mucosal Interferon response to MPXV, HIV and HPV infections in anal cells from MSM	Matteo Fracella, Roma
367	P 307	Rapid increase in syphilis diagnoses in Rome during the first quarter of 2023	Christof Stingone, Roma
382	P 308	When it rains, it pours: early treatment with tecovirimat of myopericarditis associated with monkeypox infection in a person with HIV and previously undiagnosed Lyme disease	Giuseppe Formica, Firenze
386	P 309	Neisseria gonorrhoeae in a localized septic arthritis: an unusual aetiology	Manuel Zagarrigo, Bologna
427	P 310	Analysis of STIs incidence and risk factors in a cohort of MSM attending a PrEP community-based center and the STD outpatient clinic of the Dermatology Department of S.Orsola-Malpighi Hospital in Bologna. One year follow-up data from SEX-CHECK-PLUS study	Pietro Fait, Bologna
461	P 311	Syphilis in PrEP users and PLWH attending an outpatient clinic of a large clinical centre in Rome	Rebecca Jo Steiner, Roma
497	P 312	A case of otic involvement in secondary syphilis	Michelle Abbott, Palermo
517	P 313	Case Report: A novel presentation of Neurosyphilis in a HIV-uninfected patient with fronto-temporal-parietal cerebral atrophy	Elena Matteini, Roma
531	P 314	Effectiveness of the mpox vaccination campaign and vaccine safety profile – experience of a STI clinic during 2022 epidemic	Daniele Tesoro, Milano
536	P 315	The impact of COVID-19 pandemic on STI trends and at-risk sexual behaviors. A national multicenter study	Massimo Giuliani, Roma



Elenco Poster

ID	N. pgm	Title	Author
Virology and Pharmacology			
19	P 316	Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study	Iliaria Vicenti, Siena
49	P 317	Safety evaluation of cabotegravir in zebrafish embryos	Melania Degli Antoni, Brescia
74	P 318	Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat	Simone Pagano, Milano
106	P 319	Single-cell transcriptomics of CSF and PBMC in a primary HIV infection of a subject already affected by multiple sclerosis	Isabella Abbate, Roma
144	P 320	Use of HIV genotype resistance test in Italy: a national survey	Andrea De Vito, Sassari
152	P 321	Evaluation of ELITE InGenius® integrated system for detection, quantification and monitoring of HIV-1 RNA in Cerebrospinal Fluid	Pierpaolo Paba, Roma
165	P 322	Comparison of developmental safety between doravirine and efavirenz in zebrafish (Danio rerio) embryos	Samuele Storti, Brescia
195	P 323	Large proportion of new HIV diagnoses in Northern Italy sustained by non-B subtypes with higher HIV DNA in the Effector Memory subset	Giorgio Bozzi, Milano
210	P 324	Does proviral DNA-NGS match historical genotype?	Federica Stefanelli, Genova
237	P 325	The effects of cognate peptide recognition on proviruses in expanded T cell clones in an Elite Controller	Filippo Dragoni, Siena
247	P 326	HIV Drug Resistance: Sanger Sequencing versus Next Generation Sequencing	Giada Garzillo, Genova
255	P 327	A novel NanoBRET protease sensor to sense HIV-1 PR activity in living cells	Matteo Centazzo, Milano
365	P 328	Evaluation of a new automated real-time PCR commercial test for HIV-DNA quantification in PBMC and whole blood samples	Tiziano Giacomo Alice, Torino
368	P 329	Evaluation of the HIV1 ELITE MGB assay for HIV-1 RNA quantification: comparison with the COBAS HIV-1 test	Tiziano Giacomo Alice, Torino
458	P 330	Ritonavir-boosted atazanavir dose escalation to overcome the drug-drug interaction with rifampicin: effectiveness on intracellular and plasma drug concentrations	Amedeo De Nicolò, Torino
476	P 331	The application of HIV-1 genotype resistance test: a multicentre Italian virology laboratory experience	Rossana Scutari, Milano